| Not Yet Recruiting | Intratumoral DNX-2401 for High Grade Pediatric Brain Tumors NCT07424092 | Clinica Universidad de Navarra, Universidad de Navarra | Phase 2 |
| Not Yet Recruiting | Genotype-guided Targeted Agents Plus EZH2i for Primary Refractory PTCL NCT07493330 | Ruijin Hospital | Phase 1 / Phase 2 |
| Not Yet Recruiting | The Safety and Efficacy of Daratumumab in Patients With Refractory Aplastic Anemia NCT07287228 | Institute of Hematology & Blood Diseases Hospital, China | Phase 1 / Phase 2 |
| Recruiting | xDRIVE for Florida-based Cancer Patients NCT07167381 | First Ascent Biomedical Inc. | N/A |
| Recruiting | Micropulse Laser in Treatment of Initial and Refractory Cases of Center-Involved Diabetic Macular Edema NCT07295704 | The General Authority for Teaching Hospitals and Institutes | — |
| Not Yet Recruiting | Long-term Evaluation of Percutaneous Endoscopic Caecostomy in Refractory Constipation NCT07160192 | Nantes University Hospital | — |
| Recruiting | CD7 CAR T Cells (RD13-02) in the Treatment of Relapsed/Refractory Severe Aplastic Anemia NCT06622694 | Institute of Hematology & Blood Diseases Hospital, China | Phase 1 |
| Recruiting | Clinical Trial of CD19 Targeted CAR-T Cell in Refractory Adult SLE NCT06892145 | Chongqing Precision Biotech Co., Ltd | Phase 1 |
| Recruiting | Targeting NUDT21 siRNA Drugs for Patients With Refractory Retinoblastoma NCT06424301 | Eye & ENT Hospital of Fudan University | EARLY_Phase 1 |
| Recruiting | A Dose Escalating Study of CD19/CD22/BCMA CAR-T Therapy in Relapsed/ Refractory Multiple Myeloma NCT06732232 | Shanghai Cell Therapy Group Co.,Ltd | EARLY_Phase 1 |
| Recruiting | ATLCAR.CD30.CCR4 for CD30+ HL ATLCAR.CD30.CCR4 Cells NCT06090864 | UNC Lineberger Comprehensive Cancer Center | Phase 1 / Phase 2 |
| Recruiting | Multicenter, Platform-type Clinical Study of Refractory/Recurrent Acute Myeloid Leukemia NCT06265545 | Institute of Hematology & Blood Diseases Hospital, China | N/A |
| Active Not Recruiting | Isa-Pom-Dex in Elderly/Frail Subjects With RRMM NCT05911321 | UNC Lineberger Comprehensive Cancer Center | Phase 2 |
| Unknown | GTP Regimen in the Treatment of Refractory/Recurrent HLH NCT06038422 | Beijing Friendship Hospital | Phase 3 |
| Terminated | Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/ MLL1r, NPM1 Mutatio NCT05153330 | Biomea Fusion Inc. | Phase 1 |
| Unknown | NK Cell Therapy Recurrent/Refractory Elderly AML NCT04599452 | The Second Hospital of Shandong University | Phase 1 / Phase 2 |
| Unknown | Cord Blood Derived CAR-T Cells in Refractory/Relapsed B Cell Malignancies NCT03881774 | Henan Cancer Hospital | Phase 1 |
| Unknown | CD19/20 Bispecific Nanobody-derived CAR-T Cells in B Cell Lymphoma NCT03881761 | Henan Cancer Hospital | Phase 1 |
| Unknown | CD19 CAR-T Cells With CRS Suppression Technology for r/r CD19+ Acute Lymphoblastic Leukemia NCT03275493 | Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd | Phase 1 / Phase 2 |
| Active Not Recruiting | Combination Therapy With Entinostat and Pembrolizumab in Relapsed and Refractory Lymphomas NCT03179930 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Active Not Recruiting | A Trial of "Armored" CAR T Cells Targeting CD19 For Patients With Relapsed CD19+ Hematologic Malignancies NCT03085173 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Unknown | Rhinosinusites Chroniques NCT02407275 | Institut Hospitalo-Universitaire Méditerranée Infection | N/A |
| Unknown | Phase I/II Feasibility Study Combining Brentuximab Vedotin With Second Line Salvage Chemotherapy (DHAP) in Hod NCT02280993 | Marjolein Spiering | Phase 1 |
| Completed | A Japan Phase I/II Study of Bortezomib in Relapsed or Refractory Multiple Myeloma Patients NCT00752518 | Janssen Pharmaceutical K.K. | Phase 1 / Phase 2 |